The Food and Drug Administration on Friday approved the popular weight loss drug Wegovy to reduce the risk of heart attack and stroke in adults with cardiovascular disease and obesity or who are overweight.

“Wegovy is now the first weight loss medication to also be approved to help prevent life-threatening cardiovascular events in adults with cardiovascular disease and either obesity or overweight,” said John Sharretts, the director of the diabetes and obesity division of the FDA’s Center for Drug Evaluation and Research.